title: [Use of a low molecular weight heparin, CY 222, in the treatment of consumption coagulopathy].
abstract: Among the different treatments used for consumption coagulopathies, the most contested is classical heparin because of the risk of worsening of a hemorrhagic syndrome. A low molecular weight heparin was evaluated to determine possible improvement of this risk.
  
  
  METHODS
  Treatment with CY 222 (Choay) was administered over 2 years to 29 patients (mean age 40 years, range 15-74) with coagulation coagulopathies. Diagnosis was based on the presence of 3 of the following 5 signs: platelets less than 150,000/mm, fibrinogen less than 2 g/l, QT less than 50%, ethanol test positive, PDF greater than 20 micrograms/ml. Etiology could be classed in 3 groups: gravido-puerperal (12 cases), medical disorders (15 cases), post-traumatic (2 cases). Dosage was 150 U/kg every 18 hours subcutaneously. The usual symptomatic treatment included: transfusion of red cells, frozen fresh plasma, platelets and antithrombin III as necessary. A hemorrhage syndrome was present in 16 cases. The course of the disease was evaluated on clinical findings and surveillance of hemostasis parameters; anti-Xa activity was determined in 15 patients.
  
  
  RESULTS
  Hemorrhage was arrested and biological values normalized in 22 patients (76%) including 15 (52%) survivors. In the 7 cases where the coagulopathy was not improved, the hemorrhagic syndrome persisted in 4. In the 22 successful outcomes, the hemostasis was corrected within 48 to 72 hours, with the exception of the thrombopenia, which persisted up to the 6th day. Mean anti-Xa activity was 0.32 +/- 0.16 anti-Xa U/ml.
  
  
  CONCLUSIONS
  Results of this preliminary, non-randomized study show CY 222 to be as effective as heparin in the treatment of consumption coagulopathies.
authors.affiliation: Service de Réanimation Médicale, Hôpital Central, Nancy.
authors.forename: G
authors.initials: G
authors.lastname: Audibert
authors.forename: H
authors.initials: H
authors.lastname: Lambert
authors.forename: F
authors.initials: F
authors.lastname: Toulemonde
authors.forename: P
authors.initials: P
authors.lastname: Alexandre
authors.forename: M C
authors.initials: MC
authors.lastname: Laprevote-Heully
authors.forename: P E
authors.initials: PE
authors.lastname: Bollaert
authors.forename: P
authors.initials: P
authors.lastname: Bauer
authors.forename: A
authors.initials: A
authors.lastname: Larcan
mesh_terms: D000328:Adult; D000368:Aged; D001780:Blood Coagulation Tests; D001803:Blood Transfusion; D003131:Combined Modality Therapy; D004211:Disseminated Intravascular Coagulation / Q000175:diagnosis / Q000628:therapy*; D004341:Drug Evaluation; D017707:Erythrocyte Transfusion; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010949:Plasma; D012307:Risk Factors
chemical_list: D006495:Heparin, Low-Molecular-Weight
vernacular_title: Utilisation d'une héparine de bas poids moléculaire, la CY 222, dans le traitement des coagulopathies de consommation.